1 / 23

Nondumiso

Nondumiso. Nondumiso. Nondumiso has been taking TDF/FTC/EFV (FDC) for 1 year. She had her VL, CD4 and creatine clearance done at her 1 year follow-up. She attends the clinic today for results. . Discuss in groups (5 minutes): What must you ask this patient?

adamsa
Télécharger la présentation

Nondumiso

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nondumiso

  2. Nondumiso • Nondumiso has been taking TDF/FTC/EFV (FDC) for 1 year. • She had her VL, CD4 and creatine clearance done at her 1 year follow-up. • She attends the clinic today for results. Discuss in groups (5 minutes): • What must you ask this patient? • What must you look for on examination? • What tests must you check for this patient?

  3. What must you ask this patient? • TB and STI screen: She is well and has no TB or genital symptoms. • Adherence: She started a new job 4 months ago and admits she has found it difficult to be adherent to her ART. • Side effects: She has had no side effects form her ART. • Drug Interactions: She is not taking any new drugs or over the counter medications • Family Planning and fertility intentions: She uses condoms with her partner and attends reliably for her injectable contraception. She is not planning to get pregnant in the next two years • Mental Health screen: She has no symptoms of depression or substance abuse or dementia. • NCDs: She has no CVD risk factors.

  4. What must you look for on examination? • Her vitals are normal • Her weight and stage are stable • She has no mouth or skin problems • Urine dipstix is clear • All other systems are normal

  5. What tests must you check for this patient? • Her CD4 is now 245. • Her creatine clearance is 90. • Her pap smear is normal. • Her HBsAg and RPR was negative at diagnosis. • Her viral load is 1500 (it was suppressed at 6 months on ART). What is your approach to assessing and managing Nondumiso’s VL?

  6. What is your approach to assessing and managing Nondumiso’s VL Do a thorough assessment of possible causes • A – Adherence • B – Bugs (intercurrent Infections) • C – Correct dose • D – Drug Interactions • E – Resistance •  Implement interventions, provide enhanced adherence support •  Repeat VL in 3 months to see if interventions have worked

  7. Scenario 1: Nondumiso had her VL repeated after 3 months and now attends today for the results • Her previous viral load was 1500. • She is still on TDF/FTC/EFV (FDC). • She is well and has no TB or genital symptoms. • You saw her weekly for a month, then monthly. She attended reliably with excellent pill counts. • She denies having had any side effects. • No signs of depression/ substance abuse. • Her repeat VL is 20 000 c/ml How will you mange managing Nondumiso’s VL today?

  8. Scenario 2: Nondumiso had her VL repeated after 3 months and now attends today for the results • Her previous viral load was 1500. • She is still on TDF/FTC/EFV (FDC). • All else is normal as in Scenario 1 • Her repeat VL is 550 c/ml How will you manage Nondumiso’s VL today?

  9. Feedback from Groups: Scenario 1

  10. Nondumiso’s repeat VL is 20 000c/ml • Does she meet the definition of confirmed virological failure? • Yes, she meets the definition of confirmed virological failure on an NNRTI regimen, i.e. 2 VL’s > 1000 c/ml • Should she switch to second line? • Yes • Which second line regimen would you switch her to? • AZT, 3TC, and DTG • What if she was HBV co-infected: • TDF, AZT, 3TC, DTG • Are there any blood tests you would want to do • HBsAg (was negative) and HB (AZT)

  11. Part 1

  12. Part 2 VL Monitoring – Interpreting the Results of the VL Repeated after 3 Months • Switching for virological failure will now depend on • Current regimen (NNRTI vs InSTI/PI) • Duration on ART

  13. Scenario 1: Nondumiso’s repeat VL is20 000 c/ml • Is there anything you need to discuss with the client before considering a switch from EFV to DTG? • Fertility intentions, • risks and benefits of DTG, • contraceptive choices (see next slide)

  14. Enabling a Client to Make an Informed Choice • The clinician should enable a client to make an informed choice by doing the following: 1 2 3 Understand her current pregnancy status and fertility intentions: Is she pregnant? Does she desire a pregnancy: now? or in the future? or not at all? Explain the risks and benefits of DTG vs EFV (see next slide) Remember that EFV remains a safe and effective alternative Discuss and provide a choice of contraceptive options as desired Remember that dual methods are recommended

  15. Risks and Benefits of DTG vs EFV Should she choose DTG despite recommendations, document her choice in writing in clinical notes

  16. Feedback from Groups: Scenario 2

  17. Scenario 2: Nondumiso had her VL repeated after 3 months and now attends today for the results • Her previous viral load was 1500. • She is still on TDF/FTC/EFV (FDC). • All else is normal as in Scenario 1 • Her repeat VL is 550 c/ml How will you manage Nondumiso’s VL today?

  18. Scenario 2: Nondumiso’s repeat VL is 550c/ml • Does she meet the definition of confirmed virological failure? • No, she does not have 2 VL’s > 1000 c/ml • Should she switch to second line? • No • Does she qualify for any kind of regimen change? • Yes, as her second VL was < 1000 c/ml, she qualifies for a single drug switch to DTG. • We can do a single drug switch to TLD provided we have excluded outright failure by proving that their VL’s are not persistently over 1000.

  19. Part 2 VL Monitoring – Interpreting the Results of the VL Repeated after 3 Months • Switching for virological failure will now depend on • Current regimen (NNRTI vs InSTI/PI) • Duration on ART

  20. Scenario 2: Nondumiso’s repeat VL is550 c/ml • Are there any blood tests you would want to do • No • Is there anything you need to discuss with the client before considering a switch from EFV to DTG? • Fertility intentions, • risks and benefits of DTG, • contraceptive choices (see previous slides provided in scenario 1)

  21. Enabling a Client to Make an Informed Choice • The clinician should enable a client to make an informed choice by doing the following: 1 2 3 Understand her current pregnancy status and fertility intentions: Is she pregnant? Does she desire a pregnancy: now? or in the future? or not at all? Explain the risks and benefits of DTG vs EFV (see next slide) Remember that EFV remains a safe and effective alternative Discuss and provide a choice of contraceptive options as desired Remember that dual methods are recommended

  22. Risks and Benefits of DTG vs EFV Should she choose DTG despite recommendations, document her choice in writing in clinical notes

  23. Questions and Discussion

More Related